Serono Q3 net income soars 19.8% to $170.6m

19 October 2006 09:56  [Source: ICIS news]

LONDON (ICIS news)--Swiss biopharmaceutical company Serono said on Wednesday that it had increased net income by 19.8% to $170.6m (€136m) in the third quarter on strong sales of its multiple sclerosis drug Rebif.

 

Revenues rose 9.5% to $699.1m, boosted by a 19.4% increase in royalty and licensing income, which represented 11.4% of total turnover.

 

Sales of Rebif rose 18.7% to $374.8m worldwide, and jumped 30.1% in the US to $133.3m.

 

Last month, Serono announced its sale to German drug company Merck KGaA in a proposed deal valued at $13.3bn.

 

 

By: Mark Watts
+44 20 8652 3214

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly